Form 8-K - Current report:
SEC Accession No. 0001104659-25-029580
Filing Date
2025-03-31
Accepted
2025-03-31 06:30:22
Documents
17
Period of Report
2025-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510890d1_8k.htm   iXBRL 8-K 33649
2 EXHIBIT 1.1 tm2510890d1_ex1-1.htm EX-1.1 47145
3 EXHIBIT 4.1 tm2510890d1_ex4-1.htm EX-4.1 105127
4 EXHIBIT 10.1 tm2510890d1_ex10-1.htm EX-10.1 52935
8 GRAPHIC tm2510890d1_ex1-1img002.jpg GRAPHIC 3991
  Complete submission text file 0001104659-25-029580.txt   478896

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA bcli-20250331.xsd EX-101.SCH 3036
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20250331_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20250331_pre.xml EX-101.PRE 22373
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2510890d1_8k_htm.xml XML 3691
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 25788718
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)